This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Mayo Clinic Identifier:
First received: November 1, 1999
Last updated: December 20, 2016
Last verified: May 2011

RATIONALE: Surgery to remove the pancreas, some of the small intestine, and lymph nodes may be more effective treatment for cancer of the pancreas than surgery to remove the pancreas and some of the small intestine alone. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining surgery, radiation therapy, and chemotherapy may be an effective treatment for cancer of the pancreas.

PURPOSE: Randomized phase III trial to compare the effectiveness of surgery to remove the pancreas and a portion of the small intestine with or without removing lymph nodes, followed by radiation therapy and chemotherapy, in treating patients with cancer of the pancreas.

Condition Intervention Phase
Pancreatic Cancer Drug: fluorouracil Drug: leucovorin calcium Procedure: conventional surgery Radiation: radiation therapy Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: A Prospective, Randomized Trial of Extended Lymphadenectomy in the Management of Resectable Pancreatic Cancer

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Estimated Enrollment: 100
Study Start Date: May 1997
Study Completion Date: July 2007
Primary Completion Date: August 2005 (Final data collection date for primary outcome measure)
Detailed Description:


  • Assess the overall survival of patients with resectable ductal pancreatic adenocarcinoma undergoing extended versus standard pancreatoduodenectomy.

OUTLINE: Patients are randomized to undergo standard pancreatoduodenectomy (PD) or PD with extended lymph node resection after an exploratory laparotomy.

Patients receive adjuvant chemoradiation therapy 4-6 weeks after surgery, if no metastases are evident. Radiation therapy is given every week for 5 weeks. Fluorouracil/leucovorin calcium is administered by rapid IV push daily within 2 hours of radiation on days 1-4 of week 1 and days 29-31 of week 5.

Patients are followed every 4 months for the first year, then every 6 months for the next 2 years.

PROJECTED ACCRUAL: 50 patients will be accrued per group for a total of 100 patients.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically proven adenocarcinoma of the exocrine pancreas excluding periampullary cancer
  • Resectable malignancy must be located in a region that can be encompassed by a radiation port of 20 x 20 cm
  • No evidence of extranodal metastatic disease



  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • WBC at least 3500/mm^3
  • Platelet count at least 100,000/mm^3


  • Not specified


  • Bilateral renal function as demonstrated by excretory urogram (IVP) or abdominal CT scan with contrast OR
  • Greater than 2/3 of one functioning kidney must be shielded during radiation therapy


  • Must have adequate oral nutrition (greater than 1200 calories daily)
  • Greater than 5 years since prior malignancy except:

    • Squamous cell skin cancer
    • Basal cell skin cancer
    • In situ cervical cancer
  • Not pregnant or lactating
  • Patients of reproductive potential must use effective birth control
  • No cystic neoplasms of the pancreas
  • No islet cell, periampullary or cholangiocarcinoma
  • No Federal Medical Center inmates


Biologic therapy:

  • Not specified


  • No prior chemotherapy for this disease

Endocrine therapy:

  • Not specified


  • No prior radiation therapy for this disease
  • No prior radiation therapy to the abdomen


  • Celiotomy and standardized exploration for resectability required
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00003049

United States, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
National Cancer Institute (NCI)
Study Chair: Randall K. Pearson, MD Mayo Clinic
  More Information

Responsible Party: Randall K. Pearson, M.D., Mayo Clinic Cancer Center Identifier: NCT00003049     History of Changes
Other Study ID Numbers: CDR0000065689
P30CA015083 ( U.S. NIH Grant/Contract )
974301 ( Other Identifier: Mayo Clinic Cancer Center )
G97-1302 ( Other Identifier: NCI Protocol )
152-97 ( Other Identifier: Mayo Clinic IRB )
Study First Received: November 1, 1999
Last Updated: December 20, 2016

Keywords provided by Mayo Clinic:
stage I pancreatic cancer
stage II pancreatic cancer
stage III pancreatic cancer
adenocarcinoma of the pancreas

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Protective Agents processed this record on July 21, 2017